$85.29
▼ -1.2% Today
as of Sep 4, 16:45 ET
Last 30 days
Recent Press Releases & News
Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label?
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
Is Arrowhead Pharmaceuticals (ARWR) Undervalued As SHASTA 3 And SHASTA 4 Data Impress?
Overview
52-week range
$27
$95
85% of range
Avg surprise (last 3)
+1,557%
Avg reaction (last 2)
+2.9%
50% positive
Latest IV / EM
41%
EM ±6.4% · $88 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-1.36 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $-0.93 | $-1.18 | +21.2% | -133.8% | -1.5% | earnings |
| Wed Dec 31, 2025 | Dec 2025 | $0.22 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-1.26 | $-0.94 | -34.0% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $2.75 | $-0.06 | +4,683% | — | +7.2% | earnings |
| Tue Dec 31, 2024 | Dec 2024 | $-1.39 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.38 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.02 | — | — | — | — | financials |
| Sun Dec 31, 2023 | Dec 2023 | $-1.24 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.96 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $0.45 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $75M | $74M | $264M | — | $28M | $543M | $2M | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-170M | $-141M | $41M | — | $-166M | $381M | $-161M | — |
| Net income | $-194M | $-138M | $28M | — | $-175M | $368M | $-175M | — |
| EPS (diluted) | $-1.36 | $-0.93 | $0.22 | — | $-1.26 | $2.75 | $-1.39 | — |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $1.67B | $1.84B | $1.17B | $951M | $947M | $1.14B | $571M | $695M |
| Total assets | $2.11B | $2.27B | $1.60B | $1.39B | $1.38B | $1.57B | $1.01B | $1.14B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | — | — | — | — | — | — | — | — |
| Total equity | $466M | $599M | $563M | $466M | $520M | $684M | $56M | $185M |